Thermo Fisher Scientific (NYSE:TMO) Stock Price Expected to Rise, TD Cowen Analyst Says

Key Points

• TD Cowen has raised its price target for Thermo Fisher Scientific from $612.00 to $654.00, indicating a potential upside of 16.06% from the current stock price and maintaining a "buy" rating.
• Thermo Fisher reported earnings of $5.79 per share for the quarter, surpassing analyst expectations of $5.50, with a revenue of $11.12 billion, marking a 4.9% year-over-year increase.
• Insiders, including CEO Marc N. Casper, have recently sold shares of the company, resulting in a 7.99% decrease in his ownership, with a total of 30,066 shares sold worth over $14 million in the last 90 days.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) had its price objective upped by analysts at TD Cowen from $612.00 to $654.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the medical research company's stock. TD Cowen's price target would indicate a potential upside of 16.06% from the company's current price.

Several other brokerages also recently issued reports on TMO. Robert W. Baird increased their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Leerink Partners lifted their price target on Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an "outperform" rating in a research note on Wednesday. William Blair assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating on the stock. JPMorgan Chase & Co. upped their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a report on Thursday, October 9th. Finally, UBS Group reiterated a "neutral" rating and set a $590.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday. Eighteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $595.75.

Thermo Fisher Scientific Trading Down 0.7%

Shares of TMO traded down $3.72 during trading hours on Thursday, hitting $563.48. 725,234 shares of the stock traded hands, compared to its average volume of 2,413,545. The business has a fifty day moving average of $500.65 and a 200-day moving average of $451.30. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $212.78 billion, a PE ratio of 32.53, a price-to-earnings-growth ratio of 3.22 and a beta of 0.77. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same period last year, the company earned $5.28 EPS. The firm's revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Analysts expect that Thermo Fisher Scientific will post 23.28 EPS for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last 90 days. Insiders own 0.33% of the company's stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

Large investors have recently modified their holdings of the business. CBIZ Investment Advisory Services LLC increased its position in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after purchasing an additional 33 shares during the period. Highline Wealth Partners LLC boosted its position in Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company's stock valued at $29,000 after acquiring an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new position in shares of Thermo Fisher Scientific in the 1st quarter worth about $30,000. Capital A Wealth Management LLC grew its stake in Thermo Fisher Scientific by 825.0% during the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company's stock worth $30,000 after purchasing an additional 66 shares during the period. Finally, Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $31,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.